AnaptysBio has spun off First Tracks Biotherapeutics, focusing on managing royalties for Jemperli and imsidolimab.
Quiver AI Summary
AnaptysBio, Inc. has successfully completed the spin-off of its biopharma operations into a new entity called First Tracks Biotherapeutics, Inc., allowing Anaptys to focus exclusively on managing royalty agreements for Jemperli and imsidolimab. The company aims to protect and enhance the value of these royalties for its shareholders while operating under a virtual business model that minimizes operating expenses and requires few full-time employees, targeting an EBIT margin exceeding 95%. As part of this transition, Anaptys shareholders received shares of First Tracks Bio, which will trade on Nasdaq under the symbol "TRAX," while Anaptys continues to trade under "ANAB." The management emphasizes its commitment to delivering maximum value to shareholders and operating with efficiency.
Potential Positives
- The completion of the spin-off of First Tracks Biotherapeutics allows AnaptysBio to focus exclusively on managing royalties, potentially enhancing its financial performance.
- The company's new virtual business model, involving limited full-time employees and minimal operating expenses, positions it to operate efficiently and maintain high profit margins (greater than 95% EBIT).
- The tax-free distribution of First Tracks Bio shares to Anaptys shareholders may improve shareholder value and satisfaction.
Potential Negatives
- The company is transitioning to a virtual business model, which may raise concerns about its operational stability and capabilities due to limited full-time employees (FTEs).
- Forward-looking statements indicate significant risks and uncertainties surrounding the company's ability to protect financial collaborations and return value to shareholders, which could negatively impact investor confidence.
- The use of non-GAAP financial measures, like EBIT margin, without a clear reconciliation to GAAP measures may lead to confusion and skepticism among investors regarding the company's financial health.
FAQ
What is the purpose of AnaptysBio's spin-off?
AnaptysBio's spin-off aims to focus on managing and protecting shareholder value from royalties associated with Jemperli and imsidolimab.
How does AnaptysBio operate its business model?
AnaptysBio operates under a virtual business model with minimal full-time employees and low operating expenses to maximize shareholder value.
What should shareholders expect from the spin-off?
Shareholders can expect a distribution of First Tracks Biotherapeutics shares and focused management of royalty collaborations for Jemperli and imsidolimab.
What is the EBIT margin reported by AnaptysBio?
AnaptysBio reports an EBIT margin exceeding 95%, indicating high operational profitability under its new streamlined business model.
Where can more information about AnaptysBio be found?
Additional information about AnaptysBio can be found on their official website at www.AnaptysBio.com or via their LinkedIn page.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ANAB Insider Trading Activity
$ANAB insiders have traded $ANAB stock on the open market 41 times in the past 6 months. Of those trades, 0 have been purchases and 41 have been sales.
Here’s a breakdown of recent trading of $ANAB stock by insiders over the last 6 months:
- DANIEL FAGA (President, CEO) has made 0 purchases and 13 sales selling 56,471 shares for an estimated $2,805,071.
- ERIC J LOUMEAU (CHIEF LEGAL OFFICER) has made 0 purchases and 12 sales selling 57,473 shares for an estimated $2,744,478.
- DENNIS MULROY (CHIEF FINANCIAL OFFICER) has made 0 purchases and 6 sales selling 33,511 shares for an estimated $1,549,331.
- JOHN P. SCHMID has made 0 purchases and 3 sales selling 20,645 shares for an estimated $1,158,451.
- MAGDA MARQUET has made 0 purchases and 2 sales selling 11,000 shares for an estimated $530,531.
- PAUL F. LIZZUL (Chief Medical Officer) has made 0 purchases and 4 sales selling 11,604 shares for an estimated $521,526.
- J. ANTHONY WARE sold 3,900 shares for an estimated $193,342
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ANAB Hedge Fund Activity
We have seen 86 institutional investors add shares of $ANAB stock to their portfolio, and 89 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ASSENAGON ASSET MANAGEMENT S.A. removed 839,934 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $40,720,000
- MILLENNIUM MANAGEMENT LLC removed 705,659 shares (-46.4%) from their portfolio in Q4 2025, for an estimated $34,210,348
- MORGAN STANLEY removed 521,696 shares (-33.5%) from their portfolio in Q4 2025, for an estimated $25,291,822
- SOLEUS CAPITAL MANAGEMENT, L.P. removed 491,040 shares (-78.4%) from their portfolio in Q4 2025, for an estimated $23,805,619
- AFFINITY ASSET ADVISORS, LLC added 444,692 shares (+inf%) to their portfolio in Q4 2025, for an estimated $21,558,668
- FIRST LIGHT ASSET MANAGEMENT, LLC removed 343,923 shares (-34.7%) from their portfolio in Q4 2025, for an estimated $16,673,387
- POINT72 ASSET MANAGEMENT, L.P. removed 332,638 shares (-14.7%) from their portfolio in Q4 2025, for an estimated $16,126,290
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ANAB Analyst Ratings
Wall Street analysts have issued reports on $ANAB in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Barclays issued a "Overweight" rating on 01/20/2026
- UBS issued a "Buy" rating on 01/07/2026
- Stifel issued a "Buy" rating on 12/11/2025
- HC Wainwright & Co. issued a "Buy" rating on 11/24/2025
- Wedbush issued a "Outperform" rating on 11/24/2025
To track analyst ratings and price targets for $ANAB, check out Quiver Quantitative's $ANAB forecast page.
$ANAB Price Targets
Multiple analysts have issued price targets for $ANAB recently. We have seen 9 analysts offer price targets for $ANAB in the last 6 months, with a median target of $81.0.
Here are some recent targets:
- Yasmeen Rahimi from Piper Sandler set a target price of $95.0 on 03/31/2026
- Emily Bodnar from HC Wainwright & Co. set a target price of $66.0 on 03/30/2026
- Michael Yee from UBS set a target price of $90.0 on 03/17/2026
- Martin Fan from Wedbush set a target price of $75.0 on 03/12/2026
- John Lee from Truist Securities set a target price of $50.0 on 03/09/2026
- Alex Thompson from Stifel set a target price of $85.0 on 03/05/2026
- Etzer Darout from Barclays set a target price of $79.0 on 03/04/2026
Full Release
- Focused on protecting and returning value of Jemperli and imsidolimab royalties to shareholders
-
Launches with virtual model, including limited FTEs and minimal operating expenses, and approximately $140-$145 million in net cash
SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a royalty management company, today announced the completion of its spin-off of First Tracks Biotherapeutics, Inc., its former biopharma operations business.
Anaptys will now exclusively manage the financial collaborations for Jemperli with GSK and imsidolimab with Vanda with a focus on protecting and returning the value of its royalties to shareholders.
“Anaptys begins this next chapter in a virtual business model. We are now exclusively managing royalties from our out-licensed assets, Jemperli and imsidolimab, with streamlined operations requiring limited FTEs, minimal operating expenses and providing a greater than 95% EBIT margin,” said Daniel Faga, president and chief executive officer. “This structure positions us to operate without complexity and deliver maximum value to shareholders.”
The taxable spin-off was completed today following the distribution to Anaptys shareholders of one share of First Tracks Bio common stock for every one share of Anaptys common stock owned as of the close of business on April 6, 2026, the record date for the distribution.
Anaptys will continue to trade on Nasdaq under the ticker symbol “ANAB”. First Tracks Bio common stock will begin regular-way trading today on the Nasdaq Global Select Market under the symbol “TRAX”.
About AnaptysBio
Anaptys exclusively manages the financial collaborations for
Jemperli
with GSK and imsidolimab with Vanda, with a focus on protecting and returning the value of its royalties to shareholders. To learn more, visit
www.AnaptysBio.com
or follow us on
LinkedIn
.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to whether Anaptys is able to protect its financial collaborations; and its ability to return value to its shareholders. Statements including words such as “plan,” “continue,” “expect,” or “ongoing” and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements are subject to risks and uncertainties that may cause the company’s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the company’s ability to protect its financial collaborations and return value to its shareholders, the company’s ability to operate efficiently with a limited staff, and other risks and uncertainties described under the heading “Risk Factors” in documents the company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.
This press release also includes a reference to EBIT margin which is a measure not presented in accordance with generally accepted accounting principles in the United States of America (“GAAP”), which Anaptys believes provides important perspective with respect to operational profitability. Non-GAAP financial measures may exclude items that are significant in understanding and assessing Anaptys’ financial results, should not be considered in isolation or as an alternative to GAAP measures, and should be considered only as a supplement to, and not as superior to, GAAP measures. Anaptys cannot predict with certainty the magnitude or scope of certain items that would be included in the most directly comparable GAAP measure to EBIT margin for the relevant future periods, and such items may be significant. Due to these uncertainties, Anaptys cannot provide a quantitative reconciliation of EBIT margin to the most directly comparable GAAP financial measure without unreasonable effort.
Investor Contact:
Anaptys Investor Relations
[email protected]
